Tocilizumab for giant cell arteritis (GCA) during the COVID-19 pandemic (RPS 2007), version 1: 30 July 2020, NHS England and NHS Improvement

In response to the public health emergency posed by coronavirus disease 2019 (COVID-19), NHS England and NHS Improvement have established a rapid policy development process to aid clinicians in offering best care and advice to patients with or at risk of COVID-19. This document sets out the recommendations for the use of tocilizumab in giant cell arteritis (GCA) in the context of COVID-19.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news